Viral Vector– tag –
-
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm... -
Cell and Gene Therapy Manufacturing Advances: Continuous Processing and Automated Bioreactors Tackle Scalability and Cost Challenges
News-Medical.net UK Overview Cell and gene therapy (CGT) manufacturing faces significant challenges in scalability, efficiency, and cost reduction, but new advancements in continuous processing and closed, automated bioreactor technologi... -
CAR-T’s Geography Problem: Manufacturing Bottlenecks Limit Access, Advances in Closed Systems and Bioprocessing are Key
pharmaphorum UK Overview CAR-T cell therapy's geographical accessibility is heavily dependent on its manufacturing process, with production costs, turnaround times, and available facilities directly impacting patient access. A critical b... -
ProBio’s AAV Manufacturing Excellence Accelerates UC Irvine and GlyTR Therapeutics’ Pan-Cancer CAR-T Program, Achieving 80% CAR Gene Insertion Efficiency
University of California, Irvine USA Overview ProBio's advanced AAV manufacturing technology is critically powering pre-IND research for the first-in-class pan-cancer CAR-T program developed by UC Irvine and GlyTR Therapeutics. ProBio's ... -
Porton Advanced Fortifies End-to-End ATMP CDMO Services with Over 250 Global Clients
Porton Advanced China Overview Porton Advanced is strengthening its end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs), serving over 250 global customers. The company offers cell engineering CMC services for autolo... -
MaxCyte & VectorBuilder Partner on Virus-Free Gene Delivery Platform for Ex Vivo Cell Therapies, Boosting CAR T-Cell Manufacturability
BioProcess International USA Overview CDMO VectorBuilder and MaxCyte have partnered to develop a virus-free gene delivery platform for ex vivo cell therapies, including CAR T cells. This collaboration integrates VectorBuilder's 'MiniVec'... -
Market Report: US Autologous CAR-T Cell Therapy Process Optimization Market Driven by Efficiency & Cost Reduction Needs
Intel Market Research USA Overview This article summarizes the "United States Autologous CART Cell Therapy Process Optimization Market Outlook 2026-2034" report. The US autologous CAR-T cell therapy process optimization market is driven ... -
CDMO Signal Ranks Top FDA & GMP-Compliant Lentiviral Vector Manufacturing CDMOs
CDMO Signal Global Overview CDMO Signal has released a ranking of top Lentiviral Vector (LVV) CDMOs, crucial for ex vivo gene therapy, based on FDA inspection history, GMP certification, clinical program activity, and capacity. LVVs are ... -
PackGene Biotech Accelerates Next-Gen CAR-T Development with Lentiviral and mRNA Technologies
PackGene Biotech China Overview PackGene Biotech is advancing next-generation CAR-T cell development by offering both lentiviral vector (LVV) and mRNA technologies for manufacturing. LVVs are a core technology enabling stable, long-term ... -
CDMO Strategies Advance Next-Gen Biopharma: Automated Closed Systems Tackle Manufacturing Shortages
World Pharma Today Global Overview Contract Development and Manufacturing Organizations (CDMO) strategies are evolving towards end-to-end service models to support the surge in next-generation biopharmaceuticals, especially cell and gene...
